Maya Hites

TL;DR: The DisCoVeRy trial as mentioned in this paper evaluated the clinical efficacy of remdesivir plus standard care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support.

TL;DR: A correlation between high β-lactam trough concentrations and increased occurrence of neurological deterioration in septic ICU patients is found and monitoring of β- lactam levels should be considered when deterioration of neurological status occurs during critical illness.

TL;DR: It is found that hydrophilic antimicrobials (e.g. β-lactams, vancomycin, daptomycin) were more likely to manifest altered pharmacokinetics in critically ill patients who are obese, and standard dosage regimens of most commonly used antimicroBials are sufficient to achieve PD targets.

TL;DR: Routine therapeutic drug monitoring of β-lactams should be continued in obese critically ill patients, and no differences were observed in pharmacokinetic variables between the two groups.

TL;DR: Considering that critically-ill patients are highly vulnerable and likely to experience antibiotic underexposure, and because effective initial treatment is a key determinant of clinical outcome, this work supports the use of a target of 100%T > 4xMIC, which could not only maximize efficacy but also minimize emergence of resistance.